Celularity Financial Debt Ratio

What does Celularity do? Celularity, Inc. develops off-the-shelf placental-derived allogeneic cell therapies for cancer and immune and infectious diseases. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include CAR-T cells, natural killer cells, mesenchymal-like adherent stromal cells, and exosomes targeting cancer, infectious, and degenerative diseases. The company's cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy targeting B-cell malignancies. pEXO-001 is a placental-derived exosome therapy in development. The company generates revenue through the development and commercialization of its cell therapy programs. The Cell Therapy segment focuses on developing therapies for cancer, while the Degenerative Disease segment targets conditions like osteoarthritis and neurodegenerative disorders. BioBanking involves the collection and storage of placental tissue for future therapeutic use. The primary buyers of these therapies are healthcare providers and hospitals treating patients with cancer, immune disorders, and infectious diseases. Celularity's product portfolio includes CYCART-19 for B-cell malignancies, CYNK-001 for solid tumors, and pEXO-001 for regenerative medicine. The company's target market segments are patients with cancer, immune disorders, and infectious diseases. The Degenerative Disease segment specifically addresses conditions such as osteoarthritis and neurodegenerative disorders through its cell therapy programs. BioBanking supports the company's research and development by providing a source of placental-derived cells for therapeutic development. Celularity is one of the most popular companies on Eulerpool.